Prophylactic Proton Pump Inhibitors in Upper Gastrointestinal Bleeding: Impact and Underprescription in a French Multicentric Cohort.
Gastroprotection
High risk patients
Proton pump inhibitors
Upper GI bleeding
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
12 Oct 2024
12 Oct 2024
Historique:
received:
24
06
2024
accepted:
22
09
2024
medline:
13
10
2024
pubmed:
13
10
2024
entrez:
12
10
2024
Statut:
aheadofprint
Résumé
Appropriate prescription of Proton pump inhibitors (PPIs) remains an important concern amid the rising overuse. A gap exists in the literature regarding the benefit of PPI prophylaxis and the consequences of underprescription in patients at risk for upper gastrointestinal bleeding (UGIB). This study aims to describe the characteristics of hemorrhage in relation to PPI use in patients experiencing UGIB, with a focus on high-risk individuals requiring gastroprotection. Data from a French multicentric cohort of patients experiencing UGIB were analyzed. Patients using PPI were compared to those without PPI considering bleeding etiologies and outcomes of peptic ulcer disease (PUD)-related hemorrhage. The rate of PPI use and its effect on bleeding characteristics in high-risk populations, defined based on international guidelines, were also assessed. Among 2497 included patients, 31.1% were on PPI at bleeding onset. PPI users exhibited a significantly lower rate of PUD-related bleeding in comparison with those without PPI (24.7 vs 40.8%, respectively, p < 0.0001). Similar difference was observed in high-risk populations, of whom, only 40.3% had gastroprotection with PPI before bleeding onset. PPI prophylaxis, however, did not influence the severity of bleeding in the general study population or in high-risk groups. Multivariate analysis identified age, comorbidities, and having more than two anti-thrombotic agents as predictors of severe bleeding. PPI users appear to have a lower rate of bleeding ulcers compared to non-users. However, underprescription in high-risk groups raises the need for standardized care to ensure appropriate PPI use.
Sections du résumé
BACKGROUND
BACKGROUND
Appropriate prescription of Proton pump inhibitors (PPIs) remains an important concern amid the rising overuse. A gap exists in the literature regarding the benefit of PPI prophylaxis and the consequences of underprescription in patients at risk for upper gastrointestinal bleeding (UGIB).
AIMS
OBJECTIVE
This study aims to describe the characteristics of hemorrhage in relation to PPI use in patients experiencing UGIB, with a focus on high-risk individuals requiring gastroprotection.
METHODS
METHODS
Data from a French multicentric cohort of patients experiencing UGIB were analyzed. Patients using PPI were compared to those without PPI considering bleeding etiologies and outcomes of peptic ulcer disease (PUD)-related hemorrhage. The rate of PPI use and its effect on bleeding characteristics in high-risk populations, defined based on international guidelines, were also assessed.
RESULTS
RESULTS
Among 2497 included patients, 31.1% were on PPI at bleeding onset. PPI users exhibited a significantly lower rate of PUD-related bleeding in comparison with those without PPI (24.7 vs 40.8%, respectively, p < 0.0001). Similar difference was observed in high-risk populations, of whom, only 40.3% had gastroprotection with PPI before bleeding onset. PPI prophylaxis, however, did not influence the severity of bleeding in the general study population or in high-risk groups. Multivariate analysis identified age, comorbidities, and having more than two anti-thrombotic agents as predictors of severe bleeding.
CONCLUSIONS
CONCLUSIONS
PPI users appear to have a lower rate of bleeding ulcers compared to non-users. However, underprescription in high-risk groups raises the need for standardized care to ensure appropriate PPI use.
Identifiants
pubmed: 39395925
doi: 10.1007/s10620-024-08663-8
pii: 10.1007/s10620-024-08663-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Christophe Agnello
(C)
Frédérique Alabert
(F)
Morgane Amil
(M)
Yves Arondel
(Y)
Ramuntcho Arotcarena
(R)
Jean-Pierre Arpurt
(JP)
Karim Aziz
(K)
Mathieu Baconnier
(M)
Sandrine Barge
(S)
Georges Barjonet
(G)
Julien Baudon
(J)
Lucile Bauguion
(L)
Marie Bellecoste
(M)
Serge Bellon
(S)
Alban Benezech
(A)
Aliou Berete
(A)
Chantal Berger
(C)
Jean-Guy Bertolino
(JG)
Karine Bideau
(K)
Gaëlle Billet
(G)
Massimo Bocci
(M)
Isabelle Borel
(I)
Madina Boualit
(M)
Dominique Boutroux
(D)
Slim Bramli
(S)
Pascale Catala
(P)
Claire Charpignon
(C)
Jonathan Chelly
(J)
Marie Colin
(M)
Rémi Combes
(R)
Laurent Costes
(L)
Baya Coulibaly
(B)
David Cuen
(D)
Gaëlle D'hautefeuille
(G)
Hortense Davy
(H)
Mercedes DE Lustrac
(M)
Stéphanie DE Montigny-Lenhardt
(S)
Jean-Bernard Delobel
(JB)
Anca-Stela Dobrin
(AS)
Florent Ehrhard
(F)
Khaldoun Elriz
(K)
Anouk Esch
(A)
Roger Faroux
(R)
Mathilde Fron
(M)
Cécile Garceau
(C)
Armand Garioud
(A)
Edmond Geagea
(E)
Denis Grasset
(D)
Loïc Guerbau
(L)
Jessica Haque
(J)
Florence Harnois
(F)
Frédéric Heluwaert
(F)
Denis Heresbach
(D)
Sofia Herrmann
(S)
Clémence Horaist
(C)
Mehdi Kaassis
(M)
Jean Kerneis
(J)
Carelle Koudougou
(C)
Ludovic Lagin
(L)
Margot Laly
(M)
You-Heng Lam
(YH)
Rachida Leblanc-Boubchir
(R)
Antonia Legruyer
(A)
Delphine Lemee
(D)
Christophe Locher
(C)
Dominique Louvel
(D)
Henri Lubret
(H)
Gilles Macaigne
(G)
Vincent Mace
(V)
Emmanuel Maillard
(E)
Magdalena Meszaros
(M)
Mohammed Redha Moussaoui
(MR)
Stéphane Nahon
(S)
Amélie Nobecourt
(A)
Etienne Pateu
(E)
Thierry Paupard
(T)
Arnaud Pauwels
(A)
Agnès Pelaquier
(A)
Olivier Pennec
(O)
Mathilde Petiet
(M)
Fabien Pinard
(F)
Vanessa Polin
(V)
Marc Prieto
(M)
Gilles Quartier
(G)
Vincent Quentin
(V)
André-Jean Remy
(AJ)
Marie-Pierre Ripault
(MP)
Isabelle Rosa
(I)
Thierry Salvati
(T)
Matthieu Schnee
(M)
Leila Senouci
(L)
Florence Skinazi
(F)
Nathalie Talbodec
(N)
Quentin Thiebault
(Q)
Ivan Touze
(I)
Marie Trompette
(M)
Laurent Tsakiris
(L)
Hélène Vandamme
(H)
Charlotte Vanveuren
(C)
Juliette Verlynde
(J)
Joseph Vickola
(J)
René-Louis Vitte
(RL)
Faustine Wartel
(F)
Oana Zaharia
(O)
David Zanditenas
(D)
Patrick Zavadil
(P)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Strampelli A, Cerreta F, Vučić K. Medication use among older people in Europe: Implications for regulatory assessment and co-prescription of new medicines. Br J Clin Pharmacol. 2020;86:1912–1920.
doi: 10.1111/bcp.14462
pubmed: 32644249
pmcid: 7495283
Wallerstedt SM, Fastbom J, Linke J et al. Long-term use of proton pump inhibitors and prevalence of disease-and drug-related reasons for gastroprotection-a cross-sectional population-based study: Use of proton pump inhibitors and underlying reasons. Pharmacoepidemiol Drug Saf. 2017;26:9–16.
doi: 10.1002/pds.4135
pubmed: 27859947
Torres-Bondia F, de Batlle J, Galván L et al. Evolution of the consumption trend of proton pump inhibitors in the Lleida health region between 2002 and 2015. BMC Public Health. 2022;22:818.
doi: 10.1186/s12889-022-13217-6
pubmed: 35461252
pmcid: 9035259
Targownik LE, Fisher DA, Saini SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: Expert review. Gastroenterology. 2022;162:1334–1342.
doi: 10.1053/j.gastro.2021.12.247
pubmed: 35183361
Lassalle M, Le Tri T, Bardou M et al. Use of proton pump inhibitors in adults in France: A nationwide drug utilization study. Eur J Clin Pharmacol. 2020;76:449–457.
doi: 10.1007/s00228-019-02810-1
pubmed: 31838548
Quentin V, Remy A-J, Macaigne G et al. Prognostic factors associated with upper gastrointestinal bleeding based on the French multicenter SANGHRIA trial. Endosc Int Open. 2021;09:E1504–E1511.
doi: 10.1055/a-1508-5871
Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases. 1987;40:373–383.
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Rockall TA, Logan RF, Devlin HB et al. Risk assessment after acute upper gastrointestinal haemorrhage. Gut. 1996;38:316–321.
doi: 10.1136/gut.38.3.316
pubmed: 8675081
pmcid: 1383057
Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for uppergastrointestinal haemorrhage. The Lancet. 2000;356:1318–1321.
doi: 10.1016/S0140-6736(00)02816-6
Writing Committee Members, Abraham NS, Hlatky MA et al. ACCF/ACG/AHA expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of cardiology foundation task force on expert consensus documents. Circulation. 2010;2010:2619–2633.
doi: 10.1161/CIR.0b013e318202f701
Caplan A, Fett N, Rosenbach M et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology. 2017;76:11–16.
doi: 10.1016/j.jaad.2016.02.1239
pubmed: 27986133
Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. http://www.ncbi.nlm.nih.gov/books/NBK531462/ Accessed August 26 2023
Lakshmana Kumar. Proton Pump Inhibitors (PPIs) and corticosteroids Advisory guidance on when to initiate a PPI for gastro-protection. National Health system (NHS), West Essex, clinical commission group. 2021. https://westessexccg.nhs.uk/your-health/medicines-optimisation-and-pharmacy/clinical-guidelines-and-prescribing-formularies/01-gastro-intestinal-system/3341-ppi-advisory-guidance-on-when-to-iniaite-with-corticosteroid-for-gastro-protection/file .
Roffi M, Patrono C, Collet J-P et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of cardiology (ESC). Eur Heart J. 2016;37:267–315.
doi: 10.1093/eurheartj/ehv320
pubmed: 26320110
Collet J-P, Thiele H, Barbato E et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal. 2021;42:1289–1367.
doi: 10.1093/eurheartj/ehaa575
pubmed: 32860058
Sehested TSG, Carlson N, Hansen PW et al. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. European Heart Journal. 2019;40:1963–1970.
doi: 10.1093/eurheartj/ehz104
pubmed: 30851041
Kumbhani DJ, Cannon CP, Beavers CJ et al. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease. Journal of the American College of Cardiology. 2021;77:629–658.
doi: 10.1016/j.jacc.2020.09.011
pubmed: 33250267
Lip GYH, Banerjee A, Boriani G et al. Antithrombotic therapy for atrial fibrillation. Chest. 2018;154:1121–1201.
doi: 10.1016/j.chest.2018.07.040
pubmed: 30144419
The Practice Parameters Committee of the American College of Gastroenterology, Lanza FL, Chan FKL et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–738.
Mo C. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. WJG. 2015;21:5382.
doi: 10.3748/wjg.v21.i17.5382
pubmed: 25954113
pmcid: 4419080
Ray WA, Chung CP, Murray KT et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320:2221.
doi: 10.1001/jama.2018.17242
pubmed: 30512099
pmcid: 6404233
Li L, Geraghty OC, Mehta Z et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: A population-based cohort study. The Lancet. 2017;390:490–499.
doi: 10.1016/S0140-6736(17)30770-5
Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open. 2014;4:e004587.
doi: 10.1136/bmjopen-2013-004587
pubmed: 24833682
pmcid: 4025450
EL Hajj W, Quentin V, BoudouxD’Hautefeuille G et al. Prognosis of variceal and non-variceal upper gastrointestinal bleeding in already hospitalised patients: Results from a French prospective cohort. UEG Journal. 2021;9:707–717.
doi: 10.1002/ueg2.12096
pubmed: 34102016
pmcid: 8280797
Matsuda H, Nosaka T, Akazawa Y et al. Daily usage of proton pump inhibitors may reduce the severity of critical upper gastrointestinal bleeding in elderly patients. Gastroenterology Research and Practice. 2020;2020:1–8.
doi: 10.1155/2020/7168621
Wang Y, Ye Z, Ge L et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: Systematic review and network meta-analysis. BMJ. 2020. https://doi.org/10.1136/bmj.l6744 .
doi: 10.1136/bmj.l6744
pubmed: 33323388
pmcid: 8030119
Cook D, Guyatt G. Prophylaxis against upper gastrointestinal bleeding in hospitalized patients Longo DL ed. N Engl J Med. 2018;378:2506–2516.
doi: 10.1056/NEJMra1605507
pubmed: 29949497
Lau JY, Leung WK, Wu JCY et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med. 2007;356:1631–1640.
doi: 10.1056/NEJMoa065703
pubmed: 17442905
Moayyedi P, Eikelboom JW, Bosch J et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682-691.e2.
doi: 10.1053/j.gastro.2019.05.056
pubmed: 31152740
Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002–2009 Mandell MS, ed. PLoS ONE. 2013;8:e56060.
doi: 10.1371/journal.pone.0056060
pubmed: 23418510
pmcid: 3572154
Medlock S, Eslami S, Askari M et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: A systematic review of observational studies. Clinical Gastroenterology and Hepatology. 2013;11:1259-1269.e10.
doi: 10.1016/j.cgh.2013.05.034
pubmed: 23792548
de Jong HJI, Korevaar JC, van Dijk L et al. Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: A cohort study in primary care. BMJ Open. 2013;3:e003044.
doi: 10.1136/bmjopen-2013-003044
pubmed: 23883887
pmcid: 3731714
Haastrup PF, Hansen JM, Søndergaard J et al. Proton pump inhibitor use among patients at risk of peptic ulcer bleeding: A nationwide register-based study. Scandinavian Journal of Gastroenterology. 2021;56:6–12.
doi: 10.1080/00365521.2020.1853220
pubmed: 33280480
Kurlander JE, Helminski D, Kokaly AN et al. Barriers to guideline-based use of proton pump inhibitors to prevent upper gastrointestinal bleeding. Ann Fam Med. 2022;20:5–11.
doi: 10.1370/afm.2734
pubmed: 35074761
pmcid: 8786436
Jinadu T, Radhakrishnan A, Fan L. Improving use of proton pump inhibitors with dual antiplatelet therapy in patients admitted with acute coronary syndrome. BMJ Open Qual. 2022;11:e001956.
doi: 10.1136/bmjoq-2022-001956
pubmed: 36564103
pmcid: 9791429
Martín de Argila de Prados C, Aguilera Castro L, Rodríguez de Santiago E. PPIs: Between overuse and underprescription when really necessary. Rev Esp Enferm Dig. 2015;107. http://online.reed.es/fichaArticulo.aspx?iarf=226688767-740237411275 Accessed December 26, 2023
Groenen MJM, Kuipers EJ, Hansen BE et al. Incidence of duodenal ulcers and gastric ulcers in a Western population: back to where it started. Can J Gastroenterol. 2009;23:604–608.
doi: 10.1155/2009/181059
pubmed: 19816622
pmcid: 2776548
Bardhan, Cullen, Eisner et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998;12:135–140.
doi: 10.1046/j.1365-2036.1998.00288.x
pubmed: 9692687
Hooi JKY, Lai WY, Ng WK et al. Global prevalence of helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017;153:420–429.
doi: 10.1053/j.gastro.2017.04.022
pubmed: 28456631
Vörhendi N, Soós A, Anne Engh M et al. Accuracy of the Helicobacter pylori diagnostic tests in patients with peptic ulcer bleeding: a systematic review and network meta-analysis. Therap Adv Gastroenterol. 2020;13:175628482096532.
doi: 10.1177/1756284820965324
Sonnenberg A, Turner KO, Genta RM. Low prevalence of helicobacter pylori-positive peptic ulcers in private outpatient endoscopy centers in the United States. Am J Gastroenterol. 2020;115:244–250.
doi: 10.14309/ajg.0000000000000517
pubmed: 31972622
Lindsetmo R-O, Johnsen R, Eide TJ et al. Accuracy of helicobacter pylori serology in two peptic ulcer populations and in healthy controls. World J Gastroenterol. 2008;14:5039–5045.
doi: 10.3748/wjg.14.5039
pubmed: 18763287
pmcid: 2742932
Chey WD, Leontiadis GI, Howden CW et al. ACG clinical guideline: Treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112:212–239.
doi: 10.1038/ajg.2016.563
pubmed: 28071659
Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery. 2018;53:34–78.
doi: 10.1093/ejcts/ezx334
pubmed: 29045581